Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its biologic therapeutic candidates ozekibart (INBRX-109) and INBRX-106. The company’s press releases and SEC reports describe ongoing clinical trials in solid tumors, including chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
On this page, readers can follow company-issued updates on key clinical milestones, such as topline and interim data from the registrational ChonDRAgon study of ozekibart in unresectable or metastatic conventional chondrosarcoma and expansion cohorts in colorectal cancer and Ewing sarcoma. Inhibrx Biosciences also reports on progress in its INBRX-106 Phase 2/3 trial in combination with pembrolizumab in head and neck squamous cell carcinoma and its Phase 1/2 trial in checkpoint inhibitor refractory or relapsed non-small cell lung cancer.
News items further cover financial results, capital arrangements, and corporate developments following the company’s spin-off from Inhibrx, Inc. and the sale of the INBRX-101 program to Sanofi S.A. Investors and observers can review earnings releases, descriptions of research and development spending, and commentary on the company’s clinical and regulatory plans.
Because Inhibrx Biosciences focuses on oncology and, in some communications, rare diseases, its announcements often highlight data from difficult-to-treat patient populations and regulatory designations, such as Fast Track and orphan drug status for ozekibart in chondrosarcoma. Bookmark this news feed to access the company’s own descriptions of trial outcomes, conference presentations, and other material events as they are disclosed.
Inhibrx, Inc. has announced a record date set for May 17, 2024, for the distribution of 92% of shares of its subsidiary, Inhibrx Biosciences, Inc., to its common stockholders. The distribution is expected to occur on May 29, 2024, followed by the closing of the acquisition by Sanofi on May 30, 2024. Shareholders will receive one share of SpinCo common stock for every four shares of Inhibrx common stock held. Trading under the symbol 'INBX' will entitle shareholders to the distribution, with SpinCo common stock trading under 'INXB' until the completion of the distribution.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.